Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13240455 | 0.86 | LMNA (0.62) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13265843 | 0.86 | RORC (0.59) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2954791 | 0.85 | ALDH1A1 (0.65) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29397255 | 0.85 | ALDH1A1 (0.65) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13265772 | 0.84 | ALDH1A1 (0.62) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13265779 | 0.83 | MAPT (0.52) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13265835 | 0.81 | MAPT (0.56) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13265774 | 0.81 | KMT2A (0.63) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13240478 | 0.81 | MAPT (0.63) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7372951 | 0.81 | KMT2A (0.69) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754773-B2 | Composition and synthesis of new reagents for inhibition of HIV replication | UNIVERSITY OF MASSACHUSETTS (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | REV1, MAVS, ISG15 | MAPT 2825/4885LMNA 2874/4885ALDH1A1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.